Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines for persons undergoing organ or cellular transplantation, as well as those living with immunological diseases, today announced that David-Alexandre C. Gros, M.D., Eledon’s CEO, will present at the 10 th annual SVB Leerink Global Healthcare Conference, on Wednesday, February 24 th
February 17, 2021
· 2 min read